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Background: Regional citrate anticoagulation (RCA) is being increasingly used during continuous renal
replacement therapy (CRRT) in intensive care units as an alternative to systemic heparin anticoagulation.
However, due to its availability in a variety of solutions and dialysis systems, RCA is still considered a
complex intervention, possibly leading to confusion and pitfalls in everyday practice. We therefore tested
retrospectively if the introduction of RCA as a new anticoagulation strategy for CRRT was feasible and had
not negatively impacted efficacy, safety, metabolic stability, filter lifetime, and cost-effectiveness compared to
well-established systemic heparin.
Methods: This observational, retrospective study was performed on a non-cardiac surgical and trauma intensive
care unit (ICU) in a university hospital. All charts of patients receiving one of the CRRT techniques from May 2006
to April 2010 were reviewed. The first 60 consecutive patients receiving CRRT with regional citrate anticoagulation
after its implementation in February 2008 (continuous veno-venous haemodialysis, Multifiltrate® with integrated
CiCa® system, AV 1000 S® filter, n = 60) were included in the study. The last 50 consecutive patients with systemic
heparin anticoagulation therapy (continuous veno-venous haemodiafiltration, PRISMAFLEX®, AN69® filter, n = 50),
treated immediately before the introduction of RCA, were used as a historic control group.
Results: Both treatment modalities were effective in terms of uraemia control. Patients in the citrate group
presented with significantly higher pH levels, lower ionized calcium levels, and higher sodium levels compared
with the heparin treated group, however, without notable adverse clinical events. Interestingly, mean circuit
lifetime was significantly longer in the citrate group (48.6 ± 24.2 h vs. 18.8 ± 13.5 h; p < 0.0001). Both treatment
modalities were cost-effective.
Conclusions: Our results suggest that the implementation of regional citrate anticoagulation was safe and effective.
Due to the retrospective design of the study and inherent limitations therein concerning several baseline parameters,
i.e. different filters, modes of dialysis, and flow parameters not having been standardized, we were unable to draw a
causative effect relationship. Nonetheless, our results warrant further study.
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Table 1 Composition of all dialysate solutions used in the study
CiCa® Dialysate K2 Lactasol® Hemosol BO®
Sodium (mmol/l) 133 140 140
Potassium (mmol/l) 2 0 0
Calcium (mmol/l) 0 1.75 1.75
Magnesium (mmol/l) 0.75 0.75 0.5
Chloride (mmol/l) 116.5 105 109.5
Bicarbonate (mmol/l) 20 0 32
Lactate (mmol/l) 0 40 3
Glucose (g/l) 1 0 0
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Acute kidney injury (AKI) and renal failure (ARF) are
the major challenges during critical illness and represent
a strong and independent risk factor for mortality [1].
On intensive care units, the incidence of AKI reaches
about 30 % [2]. Continuous renal replacement therapy
(CRRT) is a common treatment modality of ARF in
critically ill patients [3]. To prevent clotting of the
extracorporeal circuits, anticoagulation is required in
most cases. Regional citrate anticoagulation (RCA) is
increasingly used during CRRT on intensive care
units as an alternative to systemic heparin due to ad-
vantages concerning the risk of bleeding and heparin-
induced thrombocytopenia [4–7].
Citrate acts as an anticoagulant in the extracorporeal
system through chelation of ionized calcium. Before the
blood re-enters systemic circulation, calcium is replaced
and the systemic coagulation cascade is maintained. Cit-
rate is partially removed by filtration or dialysis and rap-
idly metabolized in the liver or other tissues. Since
citrate is metabolized to bicarbonate, effects on the acid-
base status and a trend towards metabolic alkalosis are
common. Favourable effects on the inflammatory re-
sponse in septic patients are discussed, as citrate may
act as an anti-inflammatory agent as well [8, 9].
CRRT with regional citrate anticoagulation has to
compete with well-established systemic heparin anticoa-
gulation. However, due to its availability in a variety of
solutions and dialysis systems, RCA is still considered a
complex intervention, possibly leading to confusion and
pitfalls in everyday practice [10]. We therefore tested
retrospectively if the introduction of RCA as a new
anticoagulation strategy for CRRT was feasible and had
not negatively impacted efficacy, safety, metabolic stabil-




This observational, retrospective study was performed
on a 16 bed mixed non-cardiac surgical and trauma in-
tensive care unit (ICU) in a university hospital after per-
mission of the research ethics committee of Ulm
University (“Ethikkommission der Universität Ulm”, ref-
erence number 54–14) according to the Helsinki Declar-
ation. Due to the retrospective study design, no
informed consent of an individual patient was needed.
Patients with acute kidney injury according to the RIFLE
criteria [11] and an indication for CRRT were included,
independent of the reason for renal failure. Inclusion cri-
teria were oligoanuria (<100 ml/24 h), excessive increase
of serum creatinine and urea, hyperhydration with pul-
monary edema not responsive to diuretics despite ad-
equate blood pressure, or increase of serum potassium >5.5 mmol/l due to oligoanuria. A period of CRRT of at
least 3 days as well as the availability of all data sets con-
cerning therapy on ICU was mandatory for inclusion in
the study.
In 2008, citrate anticoagulation was established as a
new anticoagulation strategy for continuous renal re-
placement therapy on a non-cardiac surgical and trauma
ICU in a university hospital. Prior to this, heparin was
used for systemic anticoagulation during CRRT. From
May 2006 to December 2007, 50 consecutive patients
were retrospectively analysed for the systemic heparin
group. After a training and introduction period of
4 weeks, regional citrate anticoagulation was established
as the sole mode of anticoagulation. Sixty consecutive
patients receiving citrate anticoagulation from February
2008 through April 2010 were included in the study. Pa-
tient charts of every patient receiving one of the CRRT
techniques from May 2006 to April 2010 were reviewed.
An Access database (Microsoft Corporation, Redmond,
USA) was created to collect anonymously demographic
data such as age, weight, reasons for admission, and dur-
ation of stay on the ICU, among others. Comorbidities,
pre-existing medication, the renal status before initiation
of CRRT, as well as the Sequential Organ Failure Assess-
ment (SOFA) score were also evaluated. Flow rates and
period of CRRT, filter lifetime of the extracorporeal sys-
tems, and metabolic parameters were collected to ana-
lyse both treatment groups.
Methods
Citrate CRRT was performed using commercially available
equipment and solutions (Multifiltrate® with integrated
CiCa® system, AV 1000 S® filter kit, CiCa® Dialysate K2, so-
dium citrate 4 %, and 0.5 M CaCl2 solution; Fresenius
Medical Care, Bad Homburg, Germany; Table 1). As a
mode of CRRT, continuous veno-venous haemodialysis
(CVVHD) with regional citrate anticoagulation was
chosen (Fig. 1) due to the fact that continuous veno-
venous haemodiafiltration (CVVHDF) was not available
for the Multifiltrate® with regional citrate anticoagulation
at the time of introduction in our ICU. To maintain stable
Fig. 1 Treatment modalities used in the study. CVVHDF continuous veno-venous haemodiafiltration, CVVHD continuous veno-venous
haemodialysis, pTT partial thromboplastin time, sec seconds, Caion ionized calcium
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protocol for adjustments of blood, dialysate, citrate, and
calcium flow was used as described previously [6].
Heparin CRRT was performed with PRISMAFLEX®
and the corresponding filter kits and fluid solutions
(AN69® filter kit, Lactasol®, or Hemosol BO®; Gambro,
Hechingen, Germany; Table 1) as continuous veno-
venous haemodiafiltration (Fig. 1). The dosage of hep-
arin was 1000 IU per hour, with a target of partial
thromboplastin time (pTT) between 40 and 60 s.
To compare the metabolic effects of both techniques,
laboratory findings were analysed in all patients. Meta-
bolic acidosis was defined by low pH (<7.35), reduced
base excess (<−3 mmol/l), and a normal or reduced
paCO2 (≤44 mmHg). Metabolic alkalosis was defined by
increased pH (>7.45), increased base excess (>3 mmol/l),
and a normal or increased paCO2 (≥36 mmHg). Hyper-
natremia was defined as a rise in serum sodium to a value
exceeding 145 mmol/l. Reimbursement for both tech-
niques was calculated on procedure-related rates accord-
ing to the German Diagnosis-Related Groups (G-DRG).
Objectives
The objectives were to evaluate exploratively the effi-
cacy, safety, metabolic stability, filter lifetime, and cost-
effectiveness of regional citrate anticoagulation during
CRRT in comparison with systemic heparin anticoagula-
tion. The chosen parameter of efficacy was the reduction
of urea during CRRT course, measured on each consecu-
tive day. Safety and metabolic stability were determined
by electrolyte concentrations and the acid-base status oneach consecutive day during the CRRT course. Filter life-
time was documented for every single filter and col-
lected in a database. Cost-effectiveness was calculated
on reimbursement (according to G-DRG) and disburse-
ment (materials only).
Statistical analysis
Statistical analysis was performed using descriptive
methods; moreover, the Mann-Whitney test, the chi-
square test, the Spearman correlation, and the log-rank
test were applied where appropriate. p < 0.05 was explor-
atively regarded as statistically significant. For statistical
calculations, GraphPad Prism 5, version 5.04, was used
(GraphPad Software Inc., La Jolla, USA).
Results
Study population
In total, we analysed 110 patients receiving CRRT with
regional citrate or systemic heparin anticoagulation from
May 2006 through April 2010. In the systemic heparin
group, 50 consecutive patients receiving CRRT from
May 2006 through December 2007 were analysed, com-
pared to 60 consecutive patients in the regional citrate
group from February 2008 to April 2010.
Baseline and demographic data
Table 2 shows the baseline and demographic parameters
of the study population. Baseline characteristics as well
as the mean SOFA scores at beginning of CRRT were
similar in both groups. Mean dose of renal replacement
therapy, mean dialysate flow, and mean ultrafiltration
Table 2 Demographic and baseline parameters of the study population
Parameter CVVHD—citrate CVVHDF—heparin p value
Number of patients (n) 60 50
Gender (n, male) 44 (73 %) 36 (72 %) n.s.
Age (years) 68 ± 12 69 ± 11 n.s.
Bodyweight (kg) 87 ± 21 86 ± 23 n.s.
Sepsis (n) 16 (27 %) 16 (32 %) n.s.
Postoperative (n) 40 (66 %) 25 (50 %) n.s.
Other reason for ICU admission (n) 4 (7 %) 9 (18 %) n.s.
SOFA score at initiation of CRRT 10 ± 3 9 ± 3 n.s.
Creatinine before present illness (μmol/l) 195 ± 139 226 ± 252 n.s.
Creatinine at initiation of CRRT (μmol/l) 337 ± 133 343 ± 179 n.s.
Urea before present illness (mmol/l) 11 ± 9 10 ± 9 n.s.
Urea at initiation of CRRT (mmol/l) 23 ± 9 22 ± 9 n.s.
Mean platelet count during CRRT (G/l) 168 ± 108 175 ± 115 n.s.
Mean dose of CRRT (ml∙h−1∙kg body weight−1) 24.0 ± 6.2 20.7 ± 5.6 0.0001
Mean blood flow (ml/min) 102 ± 12.5 100 ± 2.8 n.s.
Mean dialysate flow (ml/h) 2035 ± 307 1133 ± 283 0.0001
Mean flow
replacement fluid (ml/h)
– 563 ± 203 n.a.
Mean ultrafiltration flow (ml/h) 159 ± 55 170 ± 59 0.0001
Mechanical ventilation (n) 43 (72 %) 40 (80 %) n.s.
Cirrhosis of the liver (n) 6 (10 %) 4 (8 %) n.s.
Patients weaned from CRRT (n) 22 (37 %) 19 (38 %) n.s.
Patients receiving intermittent dialysis
at ICU discharge (n)
8 (13 %) 4 (8 %) n.s.
Fatal outcome on ICU (n) 30 (50 %) 27 (54 %) n.s.
CRRT continuous renal replacement therapy, CVVHDF continuous veno-venous haemodiafiltration, CVVHD continuous veno-venous haemodialysis, SOFA Sequential
Organ Failure Assessment, ICU intensive care unit, n.s. not significant, n.a. not applicable
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ary disorders were not an exclusion criterion for antic-
oagulation with citrate during CRRT; however, no cases
with severe liver failure were treated with citrate during
the study period (Table 2).
Efficacy
Control of uraemia was evaluated on each consecutive day
during CRRTcourse. The mean plasma urea baseline levels
at the initiation of CRRT were 22.98 ± 9.26 mmol/l in the
citrate group and 21.48 ± 9.26 mmol/l in the systemic hep-
arin group. Reduction of urea levels on day 2 was equally
effective in both groups (16.43 ± 5.71 mmol/l in the citrate
group and 17.54 ± 7.03 mmol/l in the systemic heparin
group, p = 0.43). On day 3 and day 4, reduction of urea
levels was more pronounced in the citrate group with a
statistically significant difference (12.70 ± 3.94 mmol/l vs.
16.67 ± 6.38 mmol/l on day 3 and 12.40 ± 4.39 mmol/l vs.
17.94 ± 7.30 mmol/l on day 4; p = 0.003 and p < 0.0001,
respectively).Safety and metabolic stability
Both CRRT with regional citrate anticoagulation and
with systemic heparin anticoagulation showed stable
metabolic parameters with a trend towards a metabolic
alkalosis in the citrate group, as pH was significantly
higher in the citrate group during the complete CRRT
course (p < 0.0001). In total, 14 of 60 patients (23 %) in
the citrate group developed metabolic alkalosis com-
pared to 2 out of 50 patients (4 %) in the heparin group
(p = 0.0054). Metabolic acidosis occurred in 9 of 60 pa-
tients (15 %) in the citrate group, whereas 12 of 50 pa-
tients (24 %) developed metabolic acidosis in the heparin
group (p = 0.33). In addition, base excess and bicarbon-
ate were significantly higher in the citrate group on
each consecutive day during CRRT course (p < 0.0006
and p < 0.00001, respectively). The course of pH during
CRRT from day 1 to day 7 for all patients is shown in
Fig. 2.
Values of ionized calcium during CRRT course were
significantly lower in the citrate group (p < 0.0001).
Fig. 2 Course of pH during CRRT from day 1 to day 7 for all patients.
Data are given as box plots, and whiskers represent the 10th/90th
percentile. *p< 0.05 vs. heparin. CRRT continuous renal replacement
therapy, CVVHDF continuous veno-venous haemodiafiltration, CVVHD
continuous veno-venous haemodialysis
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out of 60 patients (13 %) in the citrate group compared
to 7 patients out of 50 patients (14 %) in the heparin
group. No serious complications of hypocalcemia such
as tetany or arrhythmia were observed. During the whole
CRRT course, serum sodium was significantly higher in
the citrate group (p < 0.0001). Hypernatremia only oc-
curred in 8 patients out of 60 patients (13 %) in the cit-
rate group, whereas 7 patients out of 50 (14 %) showed
hypernatremia in the heparin group. Serum potassium
was significantly higher in the heparin group during the
whole CRRT course in all patients (p = 0.007). The
course of ionized calcium during CRRT from day 1 to
day 7 for both groups is shown in Fig. 3.
Two out of sixty patients in the citrate group
showed signs of citrate accumulation, defined by a
ratio of total serum calcium to ionized calcium >2.5.
These derangements could be managed by a reduc-
tion of the blood flow and the citrate concentration
according to a preset protocol [6]. Citrate CRRT
could be continued in all patients.Fig. 3 Course of ionized calcium during CRRT from day 1 to day 7 for all pati
percentile. *p < 0.05 vs. heparin. CRRT continuous renal replacement therapy,
veno-venous haemodialysisFilter lifetime
The mean filter lifetime was 48.6 ± 24.2 h in the citrate
group, compared to 18.8 ± 13.5 h in the heparin group
(p < 0.0001). Because of a possible bias, data were also
analysed after exclusion of the last filter running before
cessation of CRRT. These data neither showed a signifi-
cant difference between the citrate (50.1 ± 24.2 h) and
the heparin groups (18.2 ± 13.0 h). In total, 226 filters
were used in the citrate group, compared to 335 filters
in the heparin group. This resulted in a median treat-
ment time of 140.2 (68.8, 281.3) hours in the citrate
group and a median treatment time of 88.5 (38.7, 176.8)
hours in the heparin group (p = 0.0082). The median
down times were 10 (0, 21) % of total dialysis time in
the citrate group and 13 (5, 24) % of total dialysis time
in the heparin group (p = 0.1286). In addition, we
assessed a possible correlation between filter lifetime
and the dose of dialysis: We could only find a weak in-
verse correlation between filter lifetime and mean dose
of CRRT (Spearman r = −0.15; p = 0.008 in the citrate
group and Spearman r = −0.26; p < 0.0001 in the heparin
group, respectively). Filter patency of all filters is shown
in Fig. 4.Cost-effectiveness
Reimbursement for both techniques was calculated on
procedure-related rates according to G-DRG. While fil-
ter kits were more expensive in the citrate group, reim-
bursement increased due to a longer period of CRRT:
The median costs per patient were 1440 (738, 3113) € in
the citrate group and 863 (434, 1435) € in the heparin
group for the complete CRRT course (p = 0.0017). The
median reimbursement per patient was 2143 (770,
4679) € in the citrate group and 1553 (770, 2732) € in
the heparin group (p = 0.42).ents. Data are given as box plots, and whiskers represent the 10th/90th
CVVHDF continuous veno-venous haemodiafiltration, CVVHD continuous
Fig. 4 Filter lifetime of all filters used in the study. Log-rank test:
p < 0.0001 citrate vs. heparin. CRRT continuous renal replacement
therapy, CVVHDF, continuous veno-venous haemodiafiltration,
CVVHD continuous veno-venous haemodialysis
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This study addresses the implications of RCA on effi-
cacy, safety, metabolic stability, filter lifetime, and
cost-effectiveness immediately after its implementation
on a non-cardiac surgical and trauma ICU compared
to systemic heparin anticoagulation. Our main find-
ings were that (1) both treatment modalities were ef-
fective in terms of uraemia control, (2) patients in the
citrate group revealed significantly higher pH levels,
lower ionized calcium levels, and higher sodium levels
without any adverse clinical events compared to the
heparin-treated group, and (3) the mean circuit life-
time was significantly longer in the citrate group.Efficacy
Concerning the treatment efficacy of both methods,
our study revealed—concordant to previously pub-
lished data [12]—that both methods were able to
clear urea from the systemic circulation in a similar
manner. In addition, we showed a significant reduc-
tion of urea in the citrate group on day 3 and day 4
compared to the heparin group. These results may be
associated to the difference in filter lifetime of both
groups, as filters in the citrate group showed a statis-
tically longer circuit lifetime. Furthermore, longer
down times of the dialysis filters on day 3 and day 4
and a significantly lower dose of dialysis in the hep-
arin group may have contributed to the significant
urea reduction in the citrate group as well. Another
aspect in this context is the influence of nutrition on
blood urea levels: As indirect calorimetry was not
routinely used and may not be validated during
CRRT, an effect of a potential catabolic state during
critical illness cannot be excluded.Safety and metabolic stability
The patients in both groups showed stable metabolic pa-
rameters. As already published by others [13, 14], analysis
of acid-base status revealed a significantly higher incidence
of metabolic alkalosis in the citrate group. Furthermore,
analysis of calcium homeostasis showed a significant lower
level of ionized calcium in the citrate group, with no sig-
nificant difference in the incidence of hypocalcemia in
both groups. Serum sodium was significantly higher in the
citrate group with no significant difference in the inci-
dence of hypernatremia. All metabolic derangements in
the citrate group could be managed by adjustments of
blood flow, citrate flow, calcium flow, and dialysate flow
according to a preset protocol [6]. If this protocol was
strictly followed, metabolic derangements could be
monitored in time and controlled without any clinical
consequences, which is in line with previously pub-
lished data [6].
Filter lifetime
The results concerning filter lifetime have to be inter-
preted with care due to the retrospective study design
and limitations therein, i.e. different filters, mode and
dose of dialysis, and flow parameters not having been
standardized. In agreement with other trials [12–15],
filter lifetime in the citrate group was significantly
higher than in the heparin group. As the coagulation
process is calcium dependent [16], longer filter pa-
tency in the citrate group could be explained by ad-
equate inhibition of coagulation in the extracorporeal
circuit. However, in some patients, we observed early
filter or circuit clotting in the citrate group despite a
postfilter calcium level <0.30 mmol/l. These findings
may be due to non-coagulation-related factors, such as
vascular access, design of the dialysis catheter, training
of nurses, mode of CRRT, clogging, biocompatibility of
the membranes, and filter size or filter type [17]. More-
over, undetected heparin-induced thrombocytopenia may
contribute to this phenomenon [18]. In contrast to our
study, two controlled trials could not confirm a signifi-
cantly longer filter patency in the citrate group [9, 19]. Dif-
ferent modes and protocols of CRRT, as well as the use of
low-molecular-weight heparin (LMWH) may be respon-
sible for these findings [9].
Cost-effectiveness
The analysis of cost-effectiveness showed that, despite
more expensive filter kits, citrate CRRT was a cost-
effective therapy. Given that longer filter lifetimes could
have had a time-saving effect for ICU staff, regional cit-
rate anticoagulation may have helped to decrease the
workload on our intensive care unit. Unfortunately,
these time-saving effects could not be analysed in this
study due to the retrospective study design. A recently
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lower costs for citrate anticoagulation and nursing staff
for filter change [15]. However, this study was performed
in the Netherlands with a different reimbursement situ-
ation compared to Germany [15]. Therefore, these re-
sults cannot be easily extrapolated to different countries.Bleeding risk
Recently, several meta-analyses [20, 21] summarized a
significant reduction of the bleeding risk during CRRT
using regional citrate anticoagulation in critically ill pa-
tients. Our study, in contrast to most studies included in
these meta-analyses [9, 12–14, 19, 22], was performed
on a mixed surgical and trauma ICU with a high per-
centage of postoperative patients at high bleeding risk.
Therefore, it would have been of particular interest to
analyse if there was a difference in terms of bleeding
complications in the citrate group compared to systemic
heparin. In addition to several methodological problems
(change of the transfusion threshold during the study
period, indication for transfusion of blood products up
to the physician in charge), our study is clearly under-
powered to answer this question.Limitations
Our study has several limitations: The retrospective,
monocentric, observational “before and after” study de-
sign precludes the possibility of drawing causative con-
clusions. Furthermore, different filters, modes of dialysis,
and flow parameters not having been standardized are
additional confounding factors. Finally, heparin was not
specifically excluded in the care of those patients under-
going citrate-based anticoagulation, e.g. for prophylaxis
of deep vein thrombosis.Conclusions
Our results suggest that the implementation of regional
citrate anticoagulation was safe and effective. Due to the
retrospective design of the study and inherent limita-
tions therein concerning several baseline parameters, i.e.
different filters, modes of dialysis, and flow parameters
not having been standardized, we were unable to draw a
causative effect relationship. Nonetheless, our results
warrant further study.
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